文献速递流行病学与生物统计临床试验与 GCP

2025-2026年新冠、呼吸道合胞病毒和流感疫苗的最新证据

Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026.
PubMed 文献 · N Engl J Med · 2025-10-29

为应对美国疫苗咨询流程变化,对2025-2026季节新冠、呼吸道合胞病毒(RSV)和流感疫苗进行系统综述,检索PubMed/MEDLINE、Embase和Web of Science,纳入511项研究。结果显示三種疫苗对住院均有保护效果且安全性与此前一致;新冠疫苗心肌炎发生率低且与接种间隔较长相关;RSVpreF疫苗在老年人中与吉兰-巴雷综合征存在关联。

要点

  • 新冠mRNA疫苗对XBB.1.5亚型住院的合并疫苗有效性:队列研究46%,病例对照研究50%,免疫抑制成人37%。
  • 针对KP.2亚型的疫苗在病例对照研究中有效性为68%;RSV疫苗对住院有效性≥68%;流感疫苗对住院有效性成人48%、儿童67%。
  • 新冠疫苗相关心肌炎在男性青少年中发生率为每10万剂1.3至3.1例,接种间隔较长风险较低。

核心结论

  • 正在积累的同行评议证据支持2025-2026季节新冠、RSV和流感免疫接种的安全性和有效性。

研究设计与样本

  • 系统综述,检索PubMed/MEDLINE、Embase和Web of Science,纳入511项符合标准的研究。

主要发现

  • 新冠mRNA疫苗对XBB.1.5亚型住院的合并疫苗有效性:队列研究46%(95%CI 34至55),病例对照研究50%(95%CI 43至57),免疫抑制成人37%(95%CI 29至44)。
  • 病例对照研究中针对KP.2亚型的疫苗有效性为68%(95%CI 42至82)。
  • 孕产妇RSV疫苗接种、婴儿尼塞韦单抗及60岁及以上成人RSV疫苗对住院的疫苗有效性为68%或以上。
  • 流感疫苗对住院的合并疫苗有效性:18至64岁成人48%(95%CI 39至55),儿童67%(95%CI 58至75)。
  • 新冠疫苗相关心肌炎在男性青少年中发生率为每10万剂1.3至3.1例,接种间隔较长风险较低;RSVpreF疫苗在老年人中与每百万剂18.2例超额吉兰-巴雷综合征病例相关;妊娠32至36周接种未观察到与早产的显著关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunization for respiratory viruses during the 2025-2026 season. METHODS: We conducted a systematic review of U.S.-licensed immunizations against coronavirus disease 2019 (Covid-19), respiratory syncytial virus (RSV), and influenza. We searched databases on PubMed/MEDLINE, Embase, and Web of Science for updates of the most recent review by the Advisory Committee on Immunization Practices (ACIP) Evidence-to-Recommendations for each disease, which was performed during the 2023-2024 period. Outcomes included vaccine efficacy and effectiveness against hospitalization, other clinical end points, and safety. RESULTS: Of 17,263 identified references, 511 studies met the inclusion criteria. Covid-19 mRNA vaccines against the XBB.1.5 subvariant had pooled vaccine effectiveness against hospitalization of 46% (95% confidence interval [CI], 34 to 55; from cohort studies) and 50% (95% CI, 43 to 57; from case-control studies) among adults and 37% (95% CI, 29 to 44) among immunocompromised adults. In a case-control study, vaccines against the KP.2 subvariant showed an effectiveness of 68% (95% CI, 42 to 82). Maternal RSV vaccination (for infant protection), nirsevimab for infants, and RSV vaccines in adults who were 60 years of age or older showed vaccine effectiveness of 68% or more against hospitalization. Influenza vaccination had a pooled vaccine effectiveness of 48% (95% CI, 39 to 55) in adults between the ages of 18 and 64 years and 67% (95% CI, 58 to 75) in children against hospitalization. Safety profiles were consistent with previous evaluations. The diagnosis of myocarditis associated with Covid-19 vaccines occurred at rates of 1.3 to 3.1 per 100,000 doses in male adolescents, with lower risk associated with longer dosing intervals. The RSVpreF vaccine was associated with 18.2 excess cases of Guillain-Barré syndrome per million doses in older adults; a significant association with preterm birth was not observed when the vaccine was administered at 32 to 36 weeks' gestation. CONCLUSIONS: Ongoing peer-reviewed evidence supports the safety and effectiveness of immunizations against Covid-19, RSV, and influenza during the 2025-2026 season. (Funded by the Center for Infectious Disease Research and Policy and the Alumbra Innovations Foundation.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Scott J, Abers MS, Marwah HK, et al. Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026. N Engl J Med. 2025. PMID: 41160817. doi:10.1056/NEJMsa2514268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。